NMN plus MSLN CAR-NK cells in ovarian cancer: preclinical study
In this preclinical study, adding nicotinamide mononucleotide (NMN) enhanced MSLN-targeting CAR-NK cell activity against ovarian cancer cells and improved tumor control in mice; human benefit is not shown. [1]
Automatic summary · not editorially reviewed
The key findings
The study tested whether NMN improves MSLN-targeting CAR-NK cells against ovarian cancer in laboratory and mouse experiments. [1]
NMN increased CAR-NK degranulation (CD107a up 21.7 ± 1.1%) and specific lysis of target cells to 32.8 ± 1.4% at a 25:1 ratio. [1]
In an OVCAR8-MSLN xenograft mouse model, NMN-preconditioned CAR-NK cells gave better tumor control than controls. [1]
The source at a glance
- Study type / format
- Preclinical laboratory and mouse xenograft study (abstract)
- Population / context
- Human ovarian cancer cell lines and OVCAR8-MSLN xenograft mice; no human participants.
- Summary based on
- Study abstract
- Original publication
- August 13, 2026
NMN and MSLN CAR-NK cells in ovarian cancer
The study asked whether NMN, described as a metabolic modulator, could improve MSLN-targeting CAR-NK cells against ovarian cancer. CAR-NK cells are engineered natural killer cells; MSLN (mesothelin) is the target. The authors note that clinical use of these cells is limited by weak cytotoxic potency and limited persistence. This was laboratory and mouse work, not a human trial.
Supporting source [1]
Higher activation markers and lysis with NMN
With NMN supplementation, CAR-NK cells showed higher activation marker expression (CD69, NKG2D), greater degranulation (CD107a up 21.7 ± 1.1%) and more cytokine production (IFN-γ up 1.3-fold). NMN also increased CAR-NK killing of MSLN target cells, reaching 32.8 ± 1.4% specific lysis at an effector-to-target ratio of 25:1, while reducing cell apoptosis compared with controls. These are measured laboratory outcomes, not evidence of benefit in patients.
Supporting source [1]
Mouse tumor control and proposed mechanisms
In an OVCAR8-MSLN xenograft mouse model, transfer of NMN-preconditioned CAR-NK cells gave better tumor control than controls, with lower proliferation (Ki67), less angiogenesis (CD31) and more intratumoral CAR-NK infiltration. Proposed mechanisms include altered PLC-γ phosphorylation and mitochondrial redox balance; NMN reduced tumor-microenvironment-induced mitochondrial reactive oxygen species by 25.1 ± 0.8% in ovarian-cancer-conditioned medium. The authors call NMN a clinically relevant adjuvant, but this abstract reports no human data.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Results come from cell experiments and an OVCAR8-MSLN xenograft mouse model, with no human data. The authors' description of NMN as a clinically relevant adjuvant is not established by these findings.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ouyang X, Deng X, Wang Q, Chu M, Wei X, Wang M, Xiang C, Zhang P, Sun Z, Shen S, Xu Y. · europepmc.org · August 13, 2026